Treatment‐emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series

Objectives Bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) is a complete regimen for the treatment of HIV with a high barrier to resistance and few reported cases of treatment failure. We present three cases of treatment‐emergent resistance to nucleoside/nucleotide reverse transcriptas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HIV medicine 2023-11, Vol.24 (11), p.1137-1143
Hauptverfasser:	DeKoven, Samuel, Naccarato, Mark, Brumme, Chanson J., Tan, Darrell H. S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - therapeutic use Anti-HIV Agents - pharmacology Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral therapy bictegravir Drug Combinations Drug resistance Drug therapy Emtricitabine Heterocyclic Compounds, 3-Ring - therapeutic use Heterocyclic Compounds, 4 or More Rings - therapeutic use HIV HIV Infections - drug therapy HIV‐1 drug resistance Human immunodeficiency virus Humans Mutation Nucleotides RNA-directed DNA polymerase Sequences Tenofovir Tenofovir - pharmacology Tenofovir - therapeutic use tenofovir alafenamide Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!